Read the First Edition of The Lens, a new magazine by LSI arrow-icon

Overview

Valued at ~$47.6 million in 2023, the renal denervation devices market is projected to reach ~$128.7 million by 2028, increasing at a CAGR of 22% over the 2023-2028 forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and deal-tracking, curated insights, and more.
Renal denervation, or RDN, is a minimally invasive surgical technique used to treat refractory hypertension by utilizing energy ablation to alter the renal nerves. The procedure involves percutaneously interesting a steerable ablation catheter to the renal artery through a femoral sheath and a guide catheter, treating each renal artery in succession.
Products included within the scope of this analysis include:
Renal denervation catheters
This Market Snapshot is intended to provide a high-level overview of the global market for renal denervation devices, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups

Renal Denervation Devices Market Snapshot Summary

Snapshot Aspect Data and Details
Base Year for Estimate 2023
Forecast Period 2023 - 2028
Market Size in 2023 $47.6 billion
CAGR 22%
Projected Market Size in 2028 $128.7 billion

Renal Denervation Devices Market Insights

The renal denervation devices market has experienced a complex trajectory over the past decade. Despite being commercially available in Europe for over a decade, renal denervation technologies have struggled to gain traction after a significant setback in 2014, when Medtronic’s SYMPLICITY HTN-3 pivotal trial failed to meet its primary efficacy endpoint. This led to a decline in market activity, with the number of procedures in Europe peaking at 16,900 in 2014 before diminishing. However, recent positive results from trials such as SPYRAL and RADIANCE have reignited interest—particularly with the introduction of Recor’s Paradise™ Ultrasound RDN system, which received approval in November 2023, alongside Medtronic’s Symplicity Spyral™ RDN system.
Globally, hypertension affects over 1.3 billion people and contributes to more than 10 million deaths annually, creating a substantial market opportunity for innovative treatments like renal denervation. The traditional pharmaceutical approach to managing hypertension faces challenges such as patient compliance issues, highlighting the potential impact of a durable procedural solution.

Competitive Landscape

The full Market Snapshot includes a robust analysis of the competitive landscape for the renal denervation devices market. This includes estimated market revenue and market share for key players like Medtronic.
overview overview

Select Market Events

Company Date Event Type Event
Medtronic
11/2023 Regulatory Medtronic’s Symplicity Spyral RDN system received FDA approval.
Recor Medical
11/2023 Regulatory Recor’s Paradise Ultrasound RDN system received FDA approval.
Medtronic
5/2024 Regulatory Medtronic’s Symplicity Spyral RDN system received approval from the National Medica Product Administration (NMPA) in China.

Key Companies Covered

Abbott
Boston Scientific
Covidien
DeepQure
Medtronic
Metavention
Otsuka Medical
Recor Medical
SoniVie
Terumo
Buy Renal Denervation Devices Market Snapshot 2024-2028
Purchase Snapshot Demo the Full Platform

Order individually or subscribe and
get a complete intel platform.

Buy this report Subscribe to All Reports

Trusted By The Companies Pioneering What’s Next

lsi logo
Contact Customer Login

Events

Market Intelligence

Resources

Schedule an exploratory call

Request Info

17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647

714-847-3540
  • social-linkedin
  • social-instagram
  • social-twitter

© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy